SA516380194B1 - ارتباط جسم مضاد بـ FcRn لعلاج أمراض مناعة ذاتية - Google Patents

ارتباط جسم مضاد بـ FcRn لعلاج أمراض مناعة ذاتية Download PDF

Info

Publication number
SA516380194B1
SA516380194B1 SA516380194A SA516380194A SA516380194B1 SA 516380194 B1 SA516380194 B1 SA 516380194B1 SA 516380194 A SA516380194 A SA 516380194A SA 516380194 A SA516380194 A SA 516380194A SA 516380194 B1 SA516380194 B1 SA 516380194B1
Authority
SA
Saudi Arabia
Prior art keywords
antibody
amino acid
acid sequence
antigen
antibodies
Prior art date
Application number
SA516380194A
Other languages
Arabic (ar)
English (en)
Inventor
كيم سون إيون
هيونج يو تاي
كاب جونج جاي
شين دونجوك
كوك بارك سونغ
ووك كيم سونغ
سون كيم مين
كيونغ اهن هاي
يونغ هاي-يونغ
جونغ سونج يونغ
Original Assignee
هانال بيوفارما كو.,ليمتد.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by هانال بيوفارما كو.,ليمتد. filed Critical هانال بيوفارما كو.,ليمتد.
Publication of SA516380194B1 publication Critical patent/SA516380194B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rehabilitation Therapy (AREA)
SA516380194A 2014-04-30 2016-10-30 ارتباط جسم مضاد بـ FcRn لعلاج أمراض مناعة ذاتية SA516380194B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461986742P 2014-04-30 2014-04-30
PCT/KR2015/004424 WO2015167293A1 (en) 2014-04-30 2015-04-30 Antibody binding to fcrn for treating autoimmune diseases

Publications (1)

Publication Number Publication Date
SA516380194B1 true SA516380194B1 (ar) 2020-10-14

Family

ID=54358928

Family Applications (1)

Application Number Title Priority Date Filing Date
SA516380194A SA516380194B1 (ar) 2014-04-30 2016-10-30 ارتباط جسم مضاد بـ FcRn لعلاج أمراض مناعة ذاتية

Country Status (21)

Country Link
US (6) US10544226B2 (enExample)
EP (2) EP4241852A3 (enExample)
JP (1) JP6449441B2 (enExample)
KR (2) KR101889466B1 (enExample)
CN (2) CN106459215B (enExample)
AU (2) AU2015253915B2 (enExample)
CA (2) CA3095295C (enExample)
DK (1) DK3137504T5 (enExample)
EA (1) EA038470B1 (enExample)
ES (1) ES2952583T3 (enExample)
FI (1) FI3137504T3 (enExample)
HU (1) HUE062403T2 (enExample)
IL (2) IL248159B (enExample)
MX (2) MX382284B (enExample)
NZ (2) NZ737666A (enExample)
PL (1) PL3137504T3 (enExample)
PT (1) PT3137504T (enExample)
RS (1) RS64542B1 (enExample)
SA (1) SA516380194B1 (enExample)
SG (1) SG11201608208VA (enExample)
WO (1) WO2015167293A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106957365B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
KR20190015704A (ko) * 2016-04-25 2019-02-14 신티뮨, 인크. 인간화된 친화성 성숙 항-fcrn 항체
BR112019001806A2 (pt) * 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
WO2018133139A1 (zh) 2017-01-21 2018-07-26 宁波知明生物科技有限公司 芍药苷-6'-o-苯磺酸酯在治疗干燥综合征的应用
MX2019015065A (es) * 2017-06-15 2020-08-03 UCB Biopharma SRL Metodo para tratamiento de trombocitopenia inmunitaria.
BR112020011310A2 (pt) 2017-12-13 2020-11-17 Momenta Pharmaceuticals, Inc. anticorpos contra fcrn e seus métodos de uso
EA202190264A1 (ru) 2018-07-20 2021-05-20 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
JP7518821B2 (ja) 2018-10-16 2024-07-18 ユーシービー バイオファルマ エスアールエル 重症筋無力症の治療方法
CN113423426B (zh) * 2018-11-06 2025-02-18 依牧诺万科学有限公司 使用抗FcRn抗体治疗格雷夫斯眼病的方法
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
EP4061486A1 (en) * 2019-11-19 2022-09-28 Immunovant Sciences GmbH Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies
WO2021160116A1 (zh) * 2020-02-10 2021-08-19 北京拓界生物医药科技有限公司 抗FcRn抗体、其抗原结合片段及其医药用途
KR20220001482A (ko) * 2020-06-29 2022-01-05 한올바이오파마주식회사 항-FcRn 항체에 대한 제형
JP7765457B2 (ja) * 2020-08-06 2025-11-06 ステレクシス セラピューティクス，エルエルシー Ｉｌ－８抗体及びその使用方法
WO2022098084A1 (ko) * 2020-11-06 2022-05-12 고려대학교 산학협력단 Fc 알파 수용체 결합 항체
CN113484526B (zh) * 2021-08-11 2024-08-23 上海迈晋生物医药科技有限公司 一种抗FcRn抗体或其抗原结合片段生物学活性的检测方法
CN117693523A (zh) * 2021-08-13 2024-03-12 舒泰神（北京）生物制药股份有限公司 特异性识别fcrn的抗体及其用途
US20250026814A1 (en) * 2021-11-16 2025-01-23 The University Of Chicago Polypeptides for detection and treatment of coronavirus infection
CN114573698B (zh) * 2022-03-16 2023-01-06 沈阳三生制药有限责任公司 一种FcRn抗原结合蛋白及其制备方法和应用
AU2023281650A1 (en) * 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
AU2023313033A1 (en) * 2022-07-27 2025-03-13 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor
JP2025528527A (ja) 2022-09-06 2025-08-28 イミュノバント・サイエンシズ・ゲーエムベーハー 抗ＦｃＲＮ抗体を用いたグレーブス病の治療方法
KR20250084991A (ko) 2022-09-06 2025-06-11 이뮤노반트 사이언시스 게엠베하 항-FcRN 항체를 이용한 만성 염증성 탈수초성 다발성 신경병증의 치료 방법
JP2026508415A (ja) 2023-03-08 2026-03-10 イムノバント サイエンシズ ゲーエムベーハー ポリソルベート賦形剤を含む高濃度タンパク質製剤およびその製造方法
US20250034260A1 (en) 2023-07-05 2025-01-30 Sanofi Fcrn antagonists for treatment of igg-related diseases and disorders
IL325970A (en) 2023-07-16 2026-03-01 argenx BV Methods for treating chronic inflammatory demyelinating polyneuropathy
AU2024370990A1 (en) 2023-10-31 2026-05-21 IMVT Corporation Methods of improving anti-fcrn therapies
IL328082A (en) 2023-11-06 2026-06-01 Momenta Pharmaceuticals Inc Compositions and methods for treating rheumatoid arthritis
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
WO2026083290A1 (en) 2024-10-16 2026-04-23 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
CN119490588B (zh) * 2024-10-17 2026-03-06 广州康盛生物科技股份有限公司 一种抗人FcRn的VHH抗体及其应用
WO2026136830A1 (en) * 2024-12-20 2026-06-25 Paragon Therapeutics, Inc. Anti-fcrn antibodies and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2534973A1 (en) 2003-08-08 2005-02-17 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatment of auto/allo immune conditions
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
JP2008538919A (ja) 2005-04-29 2008-11-13 ザ ジャクソン ラボラトリー ＦｃＲｎ抗体およびその使用
CA2637929A1 (en) * 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
US8273351B2 (en) * 2008-04-25 2012-09-25 Dyax Corp. Fc receptor binding proteins
BR112013030352B1 (pt) * 2011-06-02 2020-05-19 Dyax Corp. anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo
KR20130071961A (ko) 2011-12-21 2013-07-01 한올바이오파마주식회사 ＦｃＲｎ 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
CA2904806C (en) 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
KR101815265B1 (ko) * 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물

Also Published As

Publication number Publication date
CN111138540A (zh) 2020-05-12
EP3137504A4 (en) 2018-02-28
DK3137504T3 (da) 2023-08-14
EP4241852A3 (en) 2023-11-15
AU2015253915B2 (en) 2018-05-10
NZ737666A (en) 2018-10-26
IL280613B (en) 2021-12-01
KR101954906B1 (ko) 2019-03-08
KR20160145779A (ko) 2016-12-20
EP4241852A2 (en) 2023-09-13
AU2018203582A1 (en) 2018-06-14
CN106459215A (zh) 2017-02-22
SG11201608208VA (en) 2016-11-29
BR112016025319A2 (pt) 2017-12-12
CA2945086A1 (en) 2015-11-05
US10544226B2 (en) 2020-01-28
CN111138540B (zh) 2023-07-25
EP3137504A1 (en) 2017-03-08
DK3137504T5 (en) 2024-10-14
EP3137504B1 (en) 2023-05-10
ES2952583T3 (es) 2023-11-02
US20190135917A1 (en) 2019-05-09
PL3137504T3 (pl) 2023-10-16
RS64542B1 (sr) 2023-09-29
MX2016014210A (es) 2017-05-01
HUE062403T2 (hu) 2023-10-28
CA3095295C (en) 2023-01-10
IL280613A (en) 2021-03-25
FI3137504T3 (fi) 2023-08-07
US20170210801A1 (en) 2017-07-27
EA038470B1 (ru) 2021-09-01
KR101889466B1 (ko) 2018-08-21
PT3137504T (pt) 2023-08-18
AU2018203582B2 (en) 2019-05-02
US11613578B2 (en) 2023-03-28
AU2015253915A1 (en) 2016-12-01
US20230235063A1 (en) 2023-07-27
IL248159B (en) 2021-02-28
IL248159A0 (en) 2016-11-30
MX382284B (es) 2025-03-13
US20250026835A1 (en) 2025-01-23
EA201692192A1 (ru) 2017-04-28
JP6449441B2 (ja) 2019-01-09
CA2945086C (en) 2020-12-29
NZ726089A (en) 2017-12-22
CA3095295A1 (en) 2015-11-05
MX2021005193A (es) 2021-09-08
KR20180093128A (ko) 2018-08-20
CN106459215B (zh) 2019-12-24
US20200109201A1 (en) 2020-04-09
JP2017522043A (ja) 2017-08-10
WO2015167293A1 (en) 2015-11-05
US20240092913A1 (en) 2024-03-21

Similar Documents

Publication Publication Date Title
US20230235063A1 (en) Antibody binding to fcrn for treating autoimmune diseases
US10280207B2 (en) FcRn-specific human antibody and composition for treatment of autoimmune diseases
SA519401906B1 (ar) أجسام مضادة ومتعددات ببتيد موجهة ضد cd127
US10336825B2 (en) Antibody binding to FcRn for treating autoimmune diseases
SA516371109B1 (ar) 1a أجسام مضادة خاصة لمركب ترابطي يشبه عامل تنكرز ورم وتركيباتها واستخدامها
EP3229829B1 (en) Method for the treatment of idiopathic pulmonary fibrosis
US8828387B2 (en) Antibody having anti-cancer activity
CA3037008A1 (en) Methods for treating cancer with bavituximab based on levels of .beta.2-glycoprotein 1, and assays therefor
US12435135B2 (en) Human CD47-targeting single-domain antibody and use thereof
CN116323657B (zh) 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
WO2022068894A1 (zh) 同时靶向pd-l1和vegf的双功能分子及其医药用途
CN119192371A (zh) 抗s100a8/a9抗体及其用途
TWI623324B (zh) 用於治療自體免疫病的與fcrn結合的抗體
JP2024520635A (ja) 抗体及びそれを生成する方法
KR20220100880A (ko) 항-fcrn 항체를 이용한 온열 자가면역 용혈성 빈혈 치료 방법
HK1230217A1 (en) Antibody binding to fcrn for treating autoimmune diseases
HK40018330B (en) Antibody binding to fcrn for treating autoimmune diseases
HK40018330A (en) Antibody binding to fcrn for treating autoimmune diseases
BR112016025319B1 (pt) Anticorpo anti-fcrn isolado, polinucleotídeos, vetor de expressão recombinante, composições e método para detectar fcrn in vitro
HK1230217B (en) Antibody binding to fcrn for treating autoimmune diseases